TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Io Biotech
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

IO Biotech presented pre-clinical data on two therapeutic cancer vaccine candidates, IO112 and IO170, at the Society for Immunotherapy of Cancer's Annual Meeting. The candidates target arginase 1 and TGF-β, demonstrating potential anti-tumor activities and immune microenvironment modulation.

Insights
IOBT   positive

Company presented promising pre-clinical data for two new vaccine candidates, highlighting potential advancements in cancer immunotherapy and plans to file an Investigational New Drug Application in 2026